Hikma Pharmaceuticals has struck a deal with Novugen to acquire its first-to-file abbreviated new drug application for anti-cancer therapy trametinib, paving the way to the coveted 180-day exclusivity status on the US generics market for the US Food and Drug Administration-approved product.
The company secured the rights to Novugen’s ANDA for the product in the US, together with a wider commercial agreement, which makes Hikma responsible for trametinib’s commercialization and marketing in the